1-甲基-5-(1H-吡咯-1-基)-1H-吡唑-4-羧酸乙酯 | 175137-01-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-5-(1H-吡咯-1-基)-1H-吡唑-4-羧酸乙酯
• 英文名称: ethyl 1-methyl-5-pyrrol-1-yl-1H-pyrazole-4-carboxylate
• 英文别名: ethyl 1-methyl-5-(pyrrol-1-yl)-pyrazole-4-carboxylate；1-methyl-5-pyrrol-1-yl-1H-pyrazole-4-carboxylic acid ethyl ester；Ethyl 1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylate；ethyl 1-methyl-5-pyrrol-1-ylpyrazole-4-carboxylate
• CAS: 175137-01-6
• 化学式: C₁₁H₁₃N₃O₂
• 分子量: 219.243
• InChiKey: MYLCLHCKBABUTD-UHFFFAOYSA-N

物化性质

• 沸点：
  373.0±27.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  49
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Name:	Ethyl 1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylate 97% Material Safety Data Sheet
Synonym:	Ethyl 1-methyl-5-(1-pyrrolyl)pyrazole-4-carboxylat
CAS:	175137-01-6

Section 1 - Chemical Product MSDS Name:Ethyl 1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylate 97% Material Safety Data Sheet
Synonym:Ethyl 1-methyl-5-(1-pyrrolyl)pyrazole-4-carboxylat

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
175137-01-6	Ethyl 1-methyl-5-(1H-pyrrol-1-yl)-1H-p	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 175137-01-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: brown
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 86 - 88 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H13N3O2
Molecular Weight: 219

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 175137-01-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1-methyl-5-(1H-pyrrol-1-yl)-1H-pyrazole-4-carboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 175137-01-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 175137-01-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 175137-01-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-甲基-5-(1H-吡咯-1-基)-1H-吡唑-4-羧酸乙酯 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 1.5h， 以97%的产率得到1-甲基-5-吡咯-1-基吡唑-4-羧酸
  参考文献：
  名称：

  西地那非的潜在类似物新型吡唑并吡咯并吡嗪的合成

  摘要：

  本文描述了新型吡唑并吡咯并吡嗪的合成，目的是获得对男性勃起功能障碍具有潜在临床意义的新的特定PDE-5抑制剂。

  DOI：

  10.1002/jhet.5570380506
• 作为产物：
  描述：

  (E)-2-氰基-3-乙氧基丙烯酸乙酯 在 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 15.0h， 生成 1-甲基-5-(1H-吡咯-1-基)-1H-吡唑-4-羧酸乙酯
  参考文献：
  名称：

  西地那非的潜在类似物新型吡唑并吡咯并吡嗪的合成

  摘要：

  本文描述了新型吡唑并吡咯并吡嗪的合成，目的是获得对男性勃起功能障碍具有潜在临床意义的新的特定PDE-5抑制剂。

  DOI：

  10.1002/jhet.5570380506

文献信息

• Adamantyl-pyrazole carboxamides as inhibitors of 11B-hydroxysteroid dehydrogenase
  申请人：Anderson Kevin William

  公开号：US20070225280A1

  公开（公告）日：2007-09-27

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了以下式（I）的化合物： 以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗诸如II型糖尿病和代谢综合征等疾病是有用的。
• Reactivity of 3-(pyrrol-1-yl)thiophenes in Pd-catalysed direct arylations
  作者：Imen Smari、Chiraz Youssef、Hamed Ben Ammar、Bechir Ben Hassine、Jean-François Soulé、Henri Doucet

  DOI：10.1016/j.tet.2015.03.022

  日期：2015.9

  in moderate to good yields with a wide variety of aryl halides; whereas the use of 1-(4-methylthiophen-3-yl)-pyrrole affords the C2-arylated thiophenes. The sequential palladium catalysed 2,5-diheteroarylation of such 3-(pyrrol-1-yl)thiophene is also reported allowing the access to thiophenes bearing two different aryl units at C2 and C5. A pyrazole bearing an ester substituent at C4 and a pyrrole

  研究了Pd催化3-（吡咯-1-基）噻吩衍生物直接芳基化的区域选择性。报道了允许噻吩环在C 2或C 5处区域选择性芳基化的条件。由以KOAc为碱，DMA为溶剂和仅1 mol％Pd（OAc）2的3-（吡咯-1-基）噻吩-2-羧酸甲酯作为催化剂，目标5-芳基噻吩以中等至良好的收率得到了多种芳基卤化物。而1-（4-甲基噻吩-3-基）-吡咯的使用提供了C2-芳基噻吩。还报道了这种3-（吡咯-1-基）噻吩的顺序钯催化的2，5-二杂芳基化，允许接近在C2和C5带有两个不同芳基单元的噻吩。仅在吡咯环上的C2处芳基化在C4处带有酯取代基的吡唑和在C5处具有吡咯取代基的吡唑。
• Pyrazoles
  申请人：Gillespie Paul

  公开号：US20060223852A1

  公开（公告）日：2006-10-05

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了公式（I）的化合物，以及其药学上可接受的盐，其中取代基如规范中所披露的那样。这些化合物及含有它们的药物组合物对于治疗疾病，例如II型糖尿病和代谢综合征等，具有用处。
• Adamantyl-pyrazole carboxamides as inhibitors of 11β-hdroxysteroid dehydrogenase
  申请人：Hoffmann-La Roche Inc.

  公开号：US07728029B2

  公开（公告）日：2010-06-01

  Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of diseases such as, for example, type II diabetes mellitus and metabolic syndrome.

  本文提供了式（I）的化合物及其药学上可接受的盐，其中取代基如规范所述。这些化合物及含有它们的药物组合物，可用于治疗疾病，例如II型糖尿病和代谢综合征。
• Optimization of Pyrazole Compounds as Antibiotic Adjuvants Active against Colistin- and Carbapenem-Resistant Acinetobacter baumannii
  作者：Filomena Sannio、Antonella Brizzi、Rosita Del Prete、Marialuce Avigliano、Tiziana Simone、Carlotta Pagli、Teresa Ferraro、Filomena De Luca、Marco Paolino、Federico Corelli、Claudia Mugnaini、Jean-Denis Docquier

  DOI：10.3390/antibiotics11121832

  日期：——

  Furthermore, an evaluation of their activity as potential antibiotic adjuvants allowed for the identification of two highly active compounds on MDR Acinetobacter baumannii, including colistin-resistant isolates. This work confirms the interest in pyrazole amides as a starting point for the optimization of synergistic antibacterial compounds active on antibiotic-resistant, Gram-negative pathogens.

  抗生素耐药性、革兰氏阴性、机会性病原体的扩散是一个日益重要的全球公共卫生问题，造成了巨大的社会经济负担。鲍曼不动杆菌分离株尽管引起的感染数量少于肠杆菌，但通常表现出多重耐药表型。碳青霉烯类耐药性也相当普遍，促使 WHO 将耐碳青霉烯类鲍曼不动杆菌列为发现和开发新抗菌剂的“关键优先事项”。在之前的工作中，我们确定了几个系列的化合物，这些化合物对相关的革兰氏阴性菌（包括鲍曼不动杆菌）显示出直接作用或协同作用。其中，两种吡唑化合物，尽管没有任何直接作用活性，在存在亚抑制浓度的粘菌素对肺炎克雷伯菌和鲍曼不动杆菌时显示出显着的协同活性，并作为合成新类似物的起点。在这项工作中，合成了一系列新的 47 种吡唑化合物。一些化合物对革兰氏阳性菌表现出显着的直接抗菌活性。此外，通过评估它们作为潜在抗生素佐剂的活性，可以鉴定出两种对 MDR 鲍曼不动杆菌具有高度活性的化合物，包括粘菌素耐药株。这项工作证实了人们